| Literature DB >> 24973819 |
Frédérique Végran1, Hélène Berger1, Romain Boidot2, Grégoire Mignot3, Mélanie Bruchard3, Magalie Dosset3, Fanny Chalmin3, Cédric Rébé4, Valentin Dérangère3, Bernhard Ryffel5, Masashi Kato6, Armelle Prévost-Blondel7, François Ghiringhelli8, Lionel Apetoh8.
Abstract
The TH9 subset of helper T cells was initially shown to contribute to the induction of autoimmune and allergic diseases, but subsequent evidence has suggested that these cells also exert antitumor activities. However, the molecular events that account for their effector properties are elusive. Here we found that the transcription factor IRF1 enhanced the effector function of TH9 cells and dictated their anticancer properties. Under TH9-skewing conditions, interleukin 1β (IL-1β) induced phosphorylation of the transcription factor STAT1 and subsequent expression of IRF1, which bound to the promoters of Il9 and Il21 and enhanced secretion of the cytokines IL-9 and IL-21 from TH9 cells. Furthermore, IL-1β-induced TH9 cells exerted potent anticancer functions in an IRF1- and IL-21-dependent manner. Our findings thus identify IRF1 as a target for controlling the function of TH9 cells.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24973819 DOI: 10.1038/ni.2925
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 25.606